Diabetes, Vol 46, Issue 6 937-940, Copyright © 1997 by American Diabetes Association

ARTICLES

Treatment with neutralizing antibodies specific for IL-1beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice

C Cailleau, A Diu-Hercend, E Ruuth, R Westwood and C Carnaud
INSERM U25, Hopital Necker, Paris, France.

Interleukin-1 (IL-1) has been shown to be involved in the pathogenesis of IDDM, but it is not clear which form, IL-1alpha or IL-1beta, is predominantly implicated. In this study, we have evaluated the contribution of IL-1beta by treating diabetes-prone nonobese diabetic (NOD) mice with specific neutralizing antibodies. First, we assessed the neutralizing potential of these antibodies in C57BL/6 mice under acute septic shock by measuring IL-1beta in sera 4 h after lipopolysaccharide injection. One milligram and 0.1 mg of anti-IL-1beta antibodies (Abs) were capable of neutralizing the IL-1beta produced, and the effect persisted for at least 5 days. Second, we evaluated the role of IL-1beta in the cyclophosphamide (CY)-accelerated model of diabetes. Nondiabetic male NOD mice were injected with 200 mg/kg CY and treated twice weekly with anti-IL-1beta Ab. The incidence of diabetes reached 76 and 100% in the control groups treated with 0.25 and 0.1 mg rabbit IgG, respectively. In contrast, only 34% of mice treated with 0.25 mg of anti-IL-1beta Ab became diabetic. In the group treated with 0.1 mg of anti-IL-1beta Ab, 89% of the mice became diabetic in the same period of time, demonstrating that the protective effect was dose dependent. Our results show that IL-1beta is a critical effector molecule in this model of IDDM and that its specific inhibition could be an attractive target for therapeutic intervention.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. R. Barshes, S. Wyllie, and J. A. Goss Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts J. Leukoc. Biol., May 1, 2005; 77(5): 587 - 597. [Abstract] [Full Text] [PDF]

				J. I. Elliott and C. F. Higgins Major Histocompatibility Complex Class I Shedding and Programmed Cell Death Stimulated Through the Proinflammatory P2X7 Receptor: A Candidate Susceptibility Gene for NOD Diabetes Diabetes, August 1, 2004; 53(8): 2012 - 2017. [Abstract] [Full Text] [PDF]

				H. E. Thomas, W. Irawaty, R. Darwiche, T. C. Brodnicki, P. Santamaria, J. Allison, and T. W.H. Kay IL-1 Receptor Deficiency Slows Progression to Diabetes in the NOD Mouse Diabetes, January 1, 2004; 53(1): 113 - 121. [Abstract] [Full Text] [PDF]

				T. Tabatabaie, A. Vasquez-Weldon, D. R. Moore, and Y. Kotake Free Radicals and the Pathogenesis of Type 1 Diabetes: {beta}-Cell Cytokine-Mediated Free Radical Generation Via Cyclooxygenase-2 Diabetes, August 1, 2003; 52(8): 1994 - 1999. [Abstract] [Full Text] [PDF]

				J. G. Mabley, P. Pacher, G. J. Southan, A. L. Salzman, and C. Szabo Nicotine Reduces the Incidence of Type I Diabetes in Mice J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 876 - 881. [Abstract] [Full Text] [PDF]

				S. T. Grey, M. B. Arvelo, W. Hasenkamp, F. H. Bach, and C. Ferran A20 Inhibits Cytokine-induced Apoptosis and Nuclear Factor {kappa}B-dependent Gene Activation in Islets J. Exp. Med., October 18, 1999; 190(8): 1135 - 1146. [Abstract] [Full Text] [PDF]

				S. V. Pakala, M. Chivetta, C. B. Kelly, and J. D. Katz In Autoimmune Diabetes the Transition from Benign to Pernicious Insulitis Requires an Islet Cell Response to Tumor Necrosis Factor alpha   J. Exp. Med., April 5, 1999; 189(7): 1053 - 1062. [Abstract] [Full Text] [PDF]

				M. Arnush, A. L. Scarim, M. R. Heitmeier, C. B. Kelly, and J. A. Corbett Potential Role of Resident Islet Macrophage Activation in the Initiation of Autoimmune Diabetes J. Immunol., March 15, 1998; 160(6): 2684 - 2691. [Abstract] [Full Text] [PDF]